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INTRODUCTION
INTRODUCTION
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Postpartum hemorrhage  is  a  major  obstetrical  complication  &  one  of  the 
important  but  preventable  causes  of  maternal  morbidity  &  mortality.  It  occurs 
suddenly,  often  is  unpredictable  & can  lead  to  maternal  death  if  it  is  severe  & 
untreated. Globally it is estimated that severe PPH (Postpartum hemorrhage) occurs 
in about 11% of women who give a live birth. The incidence is thought to be much 
higher in developing countries where many women do not have access to a skilled 
attendant at delivery and where active management of the third stage of labor may 
not be routine. It is estimated that about 14 million women suffer severe blood loss 
postpartum, and that 1% of these die as a result. A further 12% survive with severe 
morbidity.
Uterine atony remains the most common cause of PPH. Adequate retraction of 
uterus in third stage of labor is essential for separation of placenta & control of third 
stage bleeding as well as for prevention of PPH. A prolonged third stage of labor is 
often associated with increased risk of maternal mortality & morbidity due to atonic 
PPH. In modern obstetrics judicious use of oxytocics & active management of third 
stage  of  labor  is  strongly recommended especially  in women who are at  risk of 
uterine atony. Routine administration of oxytocics reduces the risk of PPH by 40%. 
Although routine use of oxytocics has become widespread for shortening third stage 
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of labor, the choice of oxytocin preparation, its efficacy & mode of administration 
varies.
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REVIEW OF LITERATURE
REVIEW OF LITERATURE
9
PPH  is  a  nightmare  to  every  obstetrician  as  it  is  sudden,  frequently 
unpredicted & could be catastrophic. In the early decades of 20th century, PPH was 
the most common cause of maternal death (Thilaganathan et al1 -1993).
The objective of prophylactic oxytocics is to ensure efficient contraction of 
the uterus after delivery of infant, thus minimizing the amount of blood loss due to 
failure of occlusion of capillaries in placental site & promote rapid separation & 
descent of placenta.
Lister, Martin & Dumoulin2  (1981) established that intravenous ergometrine 
given with crowning of head or anterior shoulder reduces the risk of hemorrhage.
Embrey et al3(1963) have shown that the incidence & severity of PPH in a 
group of normal patients given i.m syntometrine (5u  of oxytocin with 0.5 mg of 
ergometrine) with birth of anterior shoulder, was significantly less than in a similar 
group of cases given i.m ergometrine.
Fleigner  &  Hibbard4  (1966)  compared  the  advantages  &  disadvantages  of 
traditional  method  versus  the  use  of  controlled  cord  traction  with  syntometrine. 
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There was reduction in incidence of PPH from 5% to less than 2%. There was no 
increase  in  need  for  manual  removal  of  placenta  or  in  incidence  of  retained 
cotyledons or membranes.
Sorbe5 (1978) recommended that administration of oxytocics will  remain a 
cornerstone in active management of third stage of labor. He suggested that oxytocin 
i.v.  in  adequate  doses  offered  some  advantage  over  ergometrine  as  it  caused 
undisturbed physiological placental separation.
Neri et al6 (1966) introduced a new method of giving 5 units of oxytocin into 
umbilical  vein to enhance separation of placenta.  This  method has been tried by 
many  people  later  for  management  of  third  stage  and routinely  for  treatment  of 
retained placenta.
Golan et  al7  (1983)  administered  10 units  of  oxytocin diluted in  20 ml  of 
normal saline into umbilical vein in 10 patients who had retained placenta for 30 
minutes after delivery. In all cases studied, expulsion of placenta occurred in a few 
minutes. The average injection-expulsion interval was 3 minutes 40 seconds (range 
2-5 minutes).
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Using intraumbilical oxytocin 80% of patients for whom manual removal of 
placenta was indicated otherwise, were spared of the risks of general anaesthesia and 
other associated risks of manual removal like immediate trauma to the uterus and 
increased incidence of puerperal infection.
Hauksson et  al8 (1986)  evaluated this  method in  48 patients  with placenta 
retained  in  uterus  for  60minutes  after  birth.  In  22  women  the  placenta  was 
completely expelled within 9 to 50 minutes (mean19 minutes) after intraumbilical 
injection. Rest of them required manual removal, which was clearly more difficult 
than  usual  because  of  firmly  contracted  uterus.  No  cardiovascular  or  other  side 
effects were noted but one patient required immediate manual removal as she had 
severe PPH. The possible explanation for very good results of Golan et al appears to 
be due to early timing of umbilical vein injection.
Chesnut et al9  (1987) in a randomized double blind placebo controlled study 
evaluated the influence of umbilical  vein administration of  oxytocin on the third 
stage  of  labor.  There  was  no  significant  difference  in  mean  injection-placental 
expulsion interval.
Young et al10 (1988) performed randomized studies of prophylactic 
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Umbilical vein oxytocin and showed no benefits.
Thilaganathan et al1  (1993) compared active management using syntometrine 
& controlled cord traction with physiological management of third stage of labor in 
women at low risk for PPH. There was no significant difference in the estimated 
blood loss or hemoglobin drop between the 2 groups. The duration of third stage was 
significantly longer in physiological group.
A prospective study11  (2008) was carried out at Prince Zaid Ben Al-Hussein 
Hospital,  Tafilah,  Jordan.  Two  thousand  one  hundred  and  sixty  one  women 
delivering singletons during 12 consecutive months were included in their study. 
Women received either intramuscular syntometrine or intravenous oxytocin alone. 
The drugs were used either before or after the 3rd stage of labor, in order to compare 
their safety and efficacy in prevention of PPH. There was no significant difference in 
the rate of PPH for syntometrine compared to oxytocin, when used at the end of 2nd 
stage of labor (odds ratio 1.08, 95%confidence interval 0.72-1.63) or after the 3rd 
stage (odds ratio 0.93, 95% confidence interval 0.65 – 1.34).The patients receiving 
oxytocics at the end of 2nd stage of labor had significantly lower rates of PPH ,for 
both syntometrine (odds ratio 0.86, 95%CI 0.59-1.12) and oxytocin (odds ratio 0.59, 
95% CI 0.39-088), compared with those treated after 3rd stage. Oxytocin alone is as 
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effective  as  the  use  of  syntometrine  in  prevention  of  PPH,  but  associated  with 
significantly fewer maternal side effects. Oxytocics administered after the 2nd stage 
of labor compared with after the third stage (placental expulsion) are associated with 
a significantly fewer rate of postpartum bleeding.
The efficacy of syntometrine has been shown to be significantly reduced when 
it is stored in a suboptimal environment (Chua et al12 1993).
  
Oral  administration  of  ergometrine  has  been  shown  to  be  ineffective  in 
reducing postpartum blood loss (de Groot et al13, 1996) and oral preparation is not 
stable  under  simulated  tropical  conditions  (de  Groot  et  al14,  1995),  making  it 
unsuitable for tropical conditions.
In a randomized controlled study15 performed in three tertiary training centers 
in Hong Kong, 2058 patients were recruited into the study and randomized to either 
oral  misoprostol  or  i.m syntometrine.  There  was  no significant  difference  in  the 
amount of blood loss and the incidence of PPH (> 500ml) or severe PPH (> 1000ml) 
in  both  groups.  A multiparous  patient  in  syntometrine  group developed massive 
postpartum hemorrhage of 5 liters after a normal vaginal delivery because of uterine 
atony and required an abdominal hysterectomy. The incidence of prolonged third 
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stage (> 30minutes) was similar. The incidence of nausea, vomiting, headache and 
chest pain was low and similar in both groups. Twenty patients in misoprostol group 
developed high fever (> 39°C), compared to only one patient who had a temperature 
of 38C in syntometrine group. The incidence of blood transfusion was 1.5 and 1.6% 
respectively.
The review by McDonald et al16 comparing syntometrine & oxytocin revealed 
that the use of intramuscular syntometrine was assoiated with reduced risk of PPH 
with a summary odds ratio of 0.74 (95%CI-0.85), regardless of the dose of oxytocin 
used.
In  most  of  the  early  studies  comparing  oxytocin  with  syntometrine  in  the 
prevention of PPH, oxytocin was given i.m at a dose of 5units.In the study published 
by Dumoulin 2  in 1981, it was clearly stated that the dose of i.m oxytocin had to be 
changed  from 5  units  to  10  units  during  the  course  of  trial  because  of  higher 
incidence of PPH with the lower dose (12.4% versus 8.6%).
In a series of 1378 subjects, Nieminen &Jarvinen17 reported no difference in 
the PPH rate between the two drugs when given intramuscularly with an odds ratio 
of 0.56 (95%CI 0.20-1.61).
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In a double blind randomized controlled trial involving 461 patients, Mitchell 
et al18reported a significant reduction in PPH rate in the syntometrine group with an 
odds ratio of 0.37(95%CI 0.16-0.85).Combining these studies, i.m syntometrine was 
associated with a significantly lower rate of PPH than 5 units of oxytocin alone, with 
an overall summary odds ratio of 0.36 (95%CI 0.23-0.55).
Docherty and Hooper19 (1981) reported that oxytocin was associated with a 
40% increase in mean blood loss, but absolute rate of PPH was not stated.
 
McDonald et al and Khan et al20 (1995) reported no difference in PPH rate 
with  an  odds  ratio  of  0.90  (95%CI  0.75-1.07)  and  0.89  (95%CI  0.53-1.51), 
respectively. However, the use of syntometrine was associated with an increase in 
the incidence of nausea, vomiting, headache &hypertension.
Yuen et al21  (1995) reported a 40% reduction in the risk of PPH (OR 0.60, 
95%CI 0.21-0.88) & the need for  repeated oxytocic injections (OR 0.63, 95%CI 
0.44-0.89)  in  the  syntometrine  group compared  to  oxytocin  & side  effects  were 
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uncommon in both groups.  The overall  comparison of  10 units  of  intramuscular 
oxytocin with syntometrine still favors syntometrine (OR 0.81, 95%CI 0.70-0.94).
A randomized control study22 (2004) was carried out comparing the efficacy 
and side effects of sublingual misoprostol  and intravenous methylergometrine for 
active management of third stage of labor in 120 low risk pregnant women at term, 
with spontaneous onset of labor. The women were randomized to receive either two 
tablets  of  misoprostol  (200microgram/tablet)  sublingually  or  1ml  of 
methylergometrine  (0.2  mg)  intravenous  injection,  after  the  delivery  of  anterior 
shoulder  of  the  baby.  Postpartum hemorrhage  as  defined  by  hemorrhage>500ml 
occurred in 3.1% of the women in sublingual misoprostol group but none of the 
women  in  methylergometrine  group  (p>0.05).  There  was  a  need  for  additional 
oxytocic  drugs  in  5%  and  8.3%  after  methylergometrine  and  misoprostol, 
respectively (p>0.05). The change in hemoglobin levels at 24hr postpartum were 0.8 
and 0.7 gm% in methylergometrine and misoprostol group, respectively (p>0.05). In 
the misoprostol group, 6.6% women developed fever >38 degree C and 21.6% had 
shivering while  in  methylergometrine  group none  experienced these  side effects. 
Sublingual misoprostol appears to be as effective as intravenous methylergometrine 
in  the  prevention  of  PPH.  However,  larger  randomized  studies  are  needed  to 
advocate its routine use.
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A Cochrane Review23 (2004) of misoprostol versus oxytocin included 24,100 
women and compared various oral and rectal doses of misoprostol with injectable 
oxytocin.  They found that 600 microgram of misoprostol  was less effective than 
oxytocin in preventing PPH greater than 1000ml (RR, 1.36; 95%CI, 1.17-1.58). It 
was  found that  3.6% of  those  given 600 microgm misoprostol  had  a  blood loss 
greater than 500ml compared to 2.6% of those given oxytocin.
A  randomized  controlled  trial24(2004)  in  Mozambique  found  that  rectal 
misoprostol (400mg as rectal enema) was as effective as 10 IU oxytocin given i.m in 
preventing PPH. Blood loss ,duration  of third stage, or hemoglobin and hematocrit 
at 72 hours postpartum were not significantly different between the groups.
A randomized controlled trial23 from Turkey found that oral misoprostol was 
as effective as oxytocin alone in preventing PPH, but not as effective as oxytocin 
plus  methylergonovine  maleate  or  oxytocin  plus  oral  misoprostol.  A  review  of 
misoprotol use during third stage of labor, compared with both placebo and oxytocin 
or syntometrine, found that misoprostol is better than placebo in reducing the need 
for additional oxytocics but inferior to oxytocin in preventing PPH, and it requires 
more additional use of oxytocics than syntometrine.
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Cochrane  Database  Syst  Rev.2000  reported  that  the  use  of  combination 
preparation syntometrine as part of routine active management of third stage of labor 
(AMTSL) appears to be associated with a statistically significant reduction in the 
risk of PPH when compared to oxytocin where blood loss is <1000 ml. This needs to 
be weighed against the more common adverse effects  associated with the use of 
syntometrine.
Edgardo Abalos25 stated that the use of syntometrine as part of AMTSL is 
associated with significant reduction in the incidence of PPH (blood loss >500ml) 
compared  with  oxytocin  alone,  irrespective  of  the  dose  (5units  or  10units).  No 
difference  was  observed  in  severe  PPH  (>1000ml).  However  the  addition  of 
ergometrine increases the incidence of high B.P & vomiting & these undesirable 
effects  should  be  taken into  account  in  determining  the  best  therapy.  The  main 
results of the review can be summarized as follows: when 100 women were treated 
with  syntometrine  rather  than  oxytocin  alone,  3  additional  episodes  of  blood 
loss>500ml will be prevented. But at the same time one additional case of high B.P 
& 10 additional cases of vomiting will be observed.
Abudhabi  third  stage  trial26 reported  that,  prophylactic  administration  of 
oxytocin  10units  as  part  of  AMTSL,  reduces  the  incidence  of  maternal  nausea, 
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vomiting & headache & rise in blood pressure than does syntometrine 1ml without 
adversely affecting the rate of PPH.
A clinical  trial27 was  designed  to  study  618  patients  admitted  to  Zahedon 
Ghods  Birth  Center  in  2001  for  normal  delivery.  The  patients  were  randomly 
divided into  two groups.  All  pregnancies  were  singleton,  normotensive  and free 
from medical disease. After exiting the anterior shoulder of fetus, 5IU of oxytocin in 
the first group and 0.5mg ergometrine plus 5IU of oxytocin in the second group was 
injected intramuscularly. Among the first group there were 20 cases (6.47%) with 
abnormal hemorrhage, compared to 8 cases (2.58%) in the second group. There was 
a significant difference between the two groups in postpartum hemorrhage. There 
was no significant difference between two groups concerning the duration of third 
stage and the need for manual removal. The side effects were uncommon and the 
incidence of hypertension was not different between two groups. The results showed 
that  syntometrine  is  more  effective  than  oxytocin  in  preventing  postpartum 
hemorrhage.
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POSTPARTUM HEMORRHAGE
POSTPARTUM HEMORRHAGE
Definitions:
21
Loss of 500ml or more of blood per vaginum during the first 24 hours after 
delivery of  baby or  even if  blood loss  is  <500ml  but  associated  with significant 
hemodynamic changes in mother.
Massive PPH is defined as loss of >1000 or 1500ml of blood.
ACOG (American College of Obstetrics & Gynecology) defines PPH as blood loss 
which decreases the hematocit by 10% or needs a transfusion.
More  than  half  of  maternal  deaths  occurring  within  24hrs  of  delivery  are 
mostly due to PPH.
Causes of PPH:
        1. Uterine atony
        2. Genital tract trauma
        3. Coagulopathy
        4. Retained placenta
        5. Uterine inversion.  
Normally  the  control  of  hemorrhage  following  delivery  is  by  contraction  & 
retraction of myometrial fibres. This causes kinking of blood vessels & so cuts off 
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the blood flow to placental site. Failure of this mechanism resulting from disordered 
myometrial function is called uterine atony & is the most common cause of PPH.
Predisposing factors include,
      High parity
      Uterine over distention secondary to
                1. Multiple pregnancy
                2. Hydramnios
                3. Fetal macrosomia
     Prolonged labor
     Precipitate labor
     Anemia
     Chorioamnionitis
     Uterine abnormalities or fibroids
     Previous H/O PPH
     Uterine inversion
     Retained placenta
     Manual removal of placenta
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     Myometrial  relaxants -  MgSO4,  beta agonists,  diazoxide,  halothane,  calcium 
channel blockers.
     Mismanagement of third stage of labor
     Operative vaginal delivery
Prophylactic management of PPH:
    The aim in the management of PPH should be prediction & prevention.
1. Women at risk of PPH should be identified.
2. AMTSL is recommended.
3. Early sucking.
Therapeutic management of PPH:
It  requires  multidisciplinary  team  for  optimum  management.  It  involves 
simultaneous  resuscitation  of  patient  &  identification  of  cause  &  instituting 
definitive treatment.
Resuscitation: 
Quick assessment of
24
          General condition
          Blood loss
          Call for assistance
To identify the cause:
        1. Check the contractility of uterus.
        2. Rule out lower genital tract lacerations.
        3. Make sure the entirety of placenta & membranes.
DEFINITIVE TREATMENT FOR THE MANAGEMENT OF PPH
MEDICAL METHODS:
1. Intravenous infusion of 20-40 units of oxytocin in 500ml of normal saline.
2. Intramuscular PG F2alpha-250 microgm 
Supplementary procedures
1. Catheterise the bladder.
2. Uterine massage,  either manually (hand on the fundus) or bimanually (vaginal 
hand in the anterior fornix; abdominal hand on the posterior aspect of the fundus) is 
a simple and very effective first line measure and reduces bleeding even if the uterus 
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remains atonic, allowing resuscitation to take effect with a reduced blood loss.  If 
uterine  atony  continues  after  oxytocics  are  given,  bimanual  compression  is 
undertaken.
3. Ensure appropriate oxygenation.
4. Give circulatory support as necessary with colloids or blood products.
5. Maintain communication between anaesthetist and rest of team.
SURGICAL MANAGEMENT
1. The tamponade test with Senkstaken-Blackmore tube or Rusch balloon catheter.
2. Laparotomy
 a) If bimanual compression of uterus reduces the bleeding, brace sutures can be 
applied.
        B-lynch sutures
        Multiple square sutures
 b) If PPH follows placenta previa, apply
        Isthumus - cervical apposition sutures
        Undersuturing of placental bed
 c) If bimanual compression fails to control bleeding, following procedures to be 
undertaken.
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     Stepwise ligation of blood vessels including
          Uterine artery
          Ovarian artery
Descending cervical artery
          Internal iliac artery ligation
 Unilaterally followed by the opposite side
             
 d) Uterine artery embolization
 e) Hysterectomy-which is the last resort.
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THIRD STAGE OF LABOR
THIRD STAGE OF LABOR
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The third stage of labor is the time interval between delivery of baby and 
expulsion of placenta. During this stage the muscles of uterus contract downward, & 
the placenta  begins to separate  from the uterine wall.  The amount  of  blood lost 
depends on how quickly this occurs. If the uterus does not contract normally (uterine 
atony), the blood vessels at the placental site remain open, & severe bleeding results.
PHYSIOLOGY:
Normal volume of blood flow through the placenta at term is 700ml/minute. 
This  has  to  be  arrested  within  seconds  following placental  separation,  otherwise 
serious  hemorrhage  will  occur.  The  three  interrelated  physiological  mechanism 
responsible for arrest of hemorrhage are,
      1. Retraction of oblique muscle fibres in upper segment which acts as a ligature 
to the torn vessels that intervene through the muscle.
      2. Following separation, the strong uterine contraction brings the uterine walls 
into apposition so that further pressure is exerted on the placental site.
      3. There is transitory increase in activation of coagulation & fibrinolytic system 
around  the  placental  site.  So  clot  formation  in  the  torn  vessels  is  intensified. 
Placental site is covered by fibrin mesh utilizing 5-10% of circulating fibrinogen.
Any impairment in these mechanisms predisposes to severe PPH.
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MECHANISM OF PLACENTAL SEPARATION:
Schultz mechanism:
During  the  process  of  separation,  there  is  formation  of  retroplacental 
hematoma. First the central portion, later the rest of placenta is delivered inversely. 
So the fetal surface appears first with the membranes covering the maternal surface.
 Duncan mechanism:
      Edge of placenta separates first & the maternal surface appears at the vaginal 
outlet.
ACTIVE MANAGEMENT OF THIRD STAGE OF LABOR
(AMTSL)
30
AMTSL  is  an  effective  measure  of  preventing  PPH.  AMTSL  can  be  practiced 
wherever  women give birth,  including at  home,  by trained health  care providers 
linked to essential supplies. AMTSL speeds delivery of the placenta by increasing 
uterine contractions and prevents PPH by averting uterine atony.
The components of AMTSL are:
     1. Administration of an uterotonic agent within one minute after the baby is born.
     2. After the cord is clamped, delivery of placenta by controlled cord traction 
(gently pulling on the umbilical cord) with counter traction on the fundus.
     3. Fundal massage after delivery of placenta.
Uterotonic drugs:
An uterotonic drug stimulates uterine contractions. Routine administration of 
a uterotonic drug is an integral part of AMTSL & is thought to play the largest role 
in  preventing  PPH.  Injectable  oxytocin  is  preferred  over  other  uterotonic  drugs 
because it is effective quickly-2 to 3 minutes after injection; it has minimal  side 
effects, & all women can use it. If oxytocin is not available, other uterotonics may be 
used,such  as  injectable  ergometrine,  injectable  syntometrine,  or  oral  misoprostol. 
Injectable uterotonic drugs require proper storage to retain potency & prolong shelf 
life.
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Controlled Cord Traction:
     The border of one hand is placed on the mother’s abdomen below the level of 
uterine fundus suprapubically & the other hand grasps the umbilical cord & applies 
steady traction posteriorly & downwards while the uterus is being held upward to 
prevent uterine inversion
32
Fundal Massage:
      The fundus of the uterus can be felt through the wall of the abdomen.
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PHARMACOLOGY OF UTEROTONICS:
The  primary  mechanism  by  which  hemostasis  is  achieved  at  the  site  of 
placental separation during 3rd stage of labor is compression of blood vessels by well 
contracted myometrium. The following drugs are used in various ways to promote 
myometrial contractions. They are given alone or in combination.
             1. Oxytocin
             2. Methylergometrine
             3. Syntometrine
OXYTOCIN:
The synthetic form of the octapeptide of oxytocin is commercially available as 
syntocinon or pitocinon. The half life of i.v oxytocin is 3-5mts.
Onset of action:
      Intravenous - within 30-40 seconds
      Intramuscular - after 3 minutes
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Mechanism of action:
It  increases  the  frequency  &  strength  of  uterine  contraction  &  augments 
retraction of uterus.
No absolute contraindications for its use.
Deleterious effects can occur with inadvertent use of i.v oxytocics.
1. In utero death of fetus
2. Rupture uterus
Side effects:
        1. Maternal hypotension
        2. Cardiac arrhythmias
        3. Water intoxication
Water  intoxication  occurs  when  the  rate  of  infusion  is  more  than  40mU/mt  & 
oxytocin is administered in large volumes of electrolyte free solution (Whalley & 
Pritchard 1963)
It should not be given i.v as a large bolus but rather as a much more dilute solution 
by continuous i.v infusion.
When oxytocin is to be administered in high doses for a considerable period of time, 
it should be used either in normal saline or ringer lactate solution.
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SYNTOMETRINE:
        Each 1 ml ampoule of injectable solution contains 5 IU synthetic oxytocin & 
0.5 mg ergometrine maleate. Syntometrine injection is a clear, colorless solution, & 
contains maleic acid as a buffer, pH 3.2. The ampoules have two green identification 
rings.           
Pharmacology:
Syntometrine combines the rapid uterine action of oxytocin, a  nonapeptide 
hormone released by the posterior lobe of pituitary, with the sustained uterotonic 
effect of ergometrine.
Following intramuscular administration, the latent period for the occurrence of 
the uterine response is considerably shorter with syntometrine (about 2 ½ minutes) 
than with ergometrine given alone (about 7 minutes), whereas the uterotonic effect 
of  syntometrine   lasts  for  several  hours  compared  with only  ½ to  1 hour  when 
oxytocin is given alone.
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These properties make syntometrine i.m suitable for the active management of 
third stage of labor and for the prevention or treatment of postpartum hemorrhage, 
particularly in situations where for any reason the intravenous administration of an 
uterotonic agent is impracticable.
Indications:
1. Active management of third stage of labor (as a means to promote separation of 
placenta and to reduce blood loss)
2. Prevention and treatment of postpartum hemorrhage associated with uterine atony.
Contraindications:
Hypersensitivity to any one of the components
First stage of labor
Second stage of labor before crowing of baby’s head
Failure of the uterus to contract normally during labor
Severe kidney disorders
Severe liver disorders
Severe heart disorders
Vascular disease
Very high blood pressure
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Pre-eclampsia or eclampsia
Infection of blood (septicaemia or blood poisoning)
Caution is required in patients with respiratory disease and chronic anaemia.
Interactions:
Syntometrine  may  enhance  the  pressor  effect  of  vasoconstrictor  drugs  (e.g.  of 
sympathomimetic agents contained in local anaesthetics) and potentiate the uterine 
action of prostaglandins.
Halothane anaesthesia may diminish the uterotonic effect of syntometrine.
Adverse effects:
     Syntometrine may cause nausea, vomiting, uterine hypertonicity associated with 
abdominal pain, headache, dizziness and skin rashes. On rare occasions, it may give 
rise to hypertension, bradycardia, cardiac arrhythmias, chest pain or to anaphylactoid 
reactions associated with dyspnoea, hypotension, collapse or shock.
38
DOSAGE:
1ml intramuscularly following delivery of anterior shoulder, or immediately 
after delivery of child. Expulsion of placenta, which is normally separated by first 
strong  uterine  contraction  following  the  injection  of  syntometrine  should  be 
manually assisted by applying gentle fundal pressure.
Drug Transport Storage
Oxytocin
Unrefrigerated  transport 
is  possible  if  no  more 
than one month at 30°C. 
 Check  manufacturer’s 
recommendations  –  some 
manufacturers  are producing 
oxytocin  that  is  more  heat 
stable  than  previously 
available
 Temporary  storage  outside 
the  refrigerator  at  a 
maximum  of  30°C  is 
acceptable for no more than 
three months.
 If possible, keep refrigerated 
at 2–8°C.
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Syntometrine
Unrefrigerated  transport 
in the dark is  possible  if 
no more than one month 
at  30°C.  Protect  from 
freezing.
 Store in the dark.
 Keep refrigerated at 2–8°C.
 Store in closed container.
 Protect from freezing.
PREVENTION AND TREATMENT OF PPH:
1 ml  of  oxytocin i.m should be given following expulsion of  placenta,  or  when 
bleeding occurs.
If necessary, the injection may be repeated after an interval of not less than 2 hrs. 
The total dose given within 24 hrs should not exceed 3ml.
Intravenous  administration  of  syntometrine  (0.5  to  1ml  by  slow  injection)  is 
possible, but not generally recommended. It is advisable to monitor blood pressure 
during intravenous administration.
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AIM OF THE STUDY
AIM OF THE STUDY
AIM OF THE STUDY:
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          This study compares the efficacy of Syntometrine versus Oxytocin in the 
active management of third stage of labor in reducing the risk of PPH and other 
adverse third stage outcomes.
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MATERIALS AND METHODS
MATERIALS AND METHODS
STUDY DESIGN:
          Prospective case control study.
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SETTINGS:
          This randomized prospective comparative study was conducted at Institute of 
Social  Obstetrics  and Govt.  Kasturba Gandhi Hospital  for  Women and Children, 
Triplicane, Chennai, on three hundred patients,  who were admitted in labor ward 
with no known risk factors for PPH.
DURATION OF STUDY:
          From September 2008 to August 2009
METHODOLOGY:
            All patients included in the study delivered vaginally .The patients were 
assigned to 2 groups at random of 150 patients in each group.
GROUP 1:
       Syntometrine 1 ampoule is administered within one minute after delivery of the 
baby.
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GROUP 2:
       Oxytocin 10 units is administered within one minute of delivery of the baby.
INCLUSION CRITERIA:
        1. Singleton pregnancy
        2. No contraindication for oxytocin/syntometrine
        3. No obstetric or other indication that could warrant abdominal delivery
        4. No known risk factor for PPH
EXCLUSION CRITERIA:
1. Previous Caesarean section
2. Previous scarred uterus
3. Multiple pregnancy
4. Cardiac patient
5. Hepatic disorders
6. Disorders of blood coagulation
7. Past H/o third stage complications
8. Known risk factors for PPH
9. Instrumental vaginal delivery
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10.  Absolute  or  relative  risk  factors  for  spontaneous  vaginal  delivery  and hence 
posted for elective CS.
TOTAL NUMBER OF CASES:
      Three hundred patients
PROCEDURE:
The delivery was effected with the patient at the edge of the table within 1 
minute of delivery of the baby, either 10 units of injection oxytocin or 1 ampoule of 
syntometrine were given in a randomized order. The user will be unaware of the 
drug being given since all these drugs will be of the same color and the ampoules 
will  only be marked with appropriate numbers and no names will  be mentioned. 
Once  the  placenta  is  removed,  she  was  placed  over  a  blood  drape,  which  is  a 
disposable, conical, graduated plastic collection bag.
The amount of blood collected in the blood drape is measured. The average 
immeasurable blood loss due to episiotomy was taken as 50ml and the same is not 
included in the blood loss.  Similarly  when there was profuse bleeding following 
episiotomy, such patients were excluded from the study.
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RESULTS AND ANALYSIS
RESULTS AND ANALYSIS
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This study was commenced with 300 women and the outcome was analyzed 
using various parameters. The results were subjected to statistical analysis using the 
t test and chi square test.
AGE GROUP:
TABLE 1:
Age 
group
Legend Syntometrine group
(group 1)
Oxytocin 
group(group2)
Total
Frequency Percentage Frequency Percentage
<25yrs 1 105 70% 94 62.7% 199(66.3%)
26-30yr
s
2 37 24.7% 51 34% 88(29.3%)
>30yrs 3 8 5.3% 5 3.3% 13(4.3%)
TOTAL 150 100% 150 100% 300(100%)
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AGE GROUP
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Most of patients in both groups were in age group of <25yrs. 70% of cases in Group 
1 & 62.7% of cases in Group 2 were in age group <25yrs. Only 5.3% of cases in 
Group 1 & 3.3% of cases in Group 2 were in age group >30yrs.
PARITY:
62.7% of women in Group 1 & 60% of cases in Group 2 were primigravida. 37.3% 
of cases in Group 1 & 40% of cases in Group 2 belonged to multigravida.
TABLE 2:
Parity Legen
d
Syntometrine group Oxytocin group Total
(%)
Frequency % Frequenc
y
%
Primigravi 1 94 62.7% 90 60 184
50
da (61.3
%)
Multigravi
da
2 56 37.3% 60 40 116
(38.7
%)
Total 150 100% 150 100% 300
100%
    PARITY
2.001.00
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90
80
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GROUP
    1.00
    2.00
SOCIOECONOMIC STATUS:
TABLE 3:
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Socioeconomic 
Status
Legend Syntometrin
e 
Group
Oxytocin
Group
Total
Frequency Percentage Frequenc
y
Percentage
Class 4 4 72 48% 77 51.3% 149
49.7%
Class 5 5 78 52% 73 48.7% 151
50.3%
Total 150 100% 150 100% 300
100%
                      
                
SOCIO ECONOMIC  STATUS
5.004.00
C
ou
nt
79
78
77
76
75
74
73
72
71
GROUP
    1.00
    2.00
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48%  of  cases  in  group  1  &  51.3%  of  cases  in  group  2  belonged  to  class  4 
socioeconomic  status.  52%  of  cases  in  group  1  &  48.7%  of  cases  in  group  2 
belonged to class 5 socioeconomic status.
BOOKING:
All patients in our study group were booked cases,  though they were selected at 
random basis.
TABLE 4:
Booking Legend Syntometrin
e
group
Oxytocin 
Group
Total
Frequency Percentage Frequenc
y
Percentage
Booked 1 150 100% 150 100% 300
100%
Unbooked 2 0 - 0 -
Total 150 100% 150 100% 300
100%
53
ONSET OF LABOR:
TABLE 5:
Onset 
of labor
Legen
d
Syntometrine group Oxytocin  Group Total
Frequen
cy
Percentag
e
Frequenc
y
Percentag
e
Sponta
n
Eous
1 96 64% 54 36% 150
(50%)
Oxytoc
in
Inducti
on
2 37 24.7% 89 59.3% 126
(42%)
PGE2 
gel
Inducti
on
3 11 7.3% 7 4.7% 18(6%)
PGE2
gel
Follow
ed
4 6 4% 0 0% 6(2%)
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by 
oxytoci
n
Total 150 100% 150 100% 300(100%
)
The % is calculated for the individual number of cases in the respective groups (150 
in each group) and for 300 cases in the grand total. 
ON SET OF  LABOUR
4.003.002.001.00
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64% of cases in group 1 & 36% of cases in group 2 had spontaneous onset of labor. 
24.7% of cases in group 1 & 59.3% of cases in group 2 were induced with oxytocin. 
7.3% 0f cases in group 1 & 4.7% of cases in group 2 were induced with PGE2 gel. 
4% of cases in group 1 & none of the case in group 2 were induced with PGE2 gel 
followed by oxytocin.
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MODE OF DELIVERY:
Most  of  the cases in group 1 (62%) & group 2 (62%) were delivered by Labor 
natural with episiotomy.
TABLE 6:
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MODE OF  DELIVERY
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DURATION OF THIRD STAGE OF LABOR:
TABLE 7:
Frequenc Mean duration of third
Mode of
Delivery
Legend Syntometrine Group Oxytocin  Group Total
Frequenc
y
Percentage Frequenc
y
Percentage
Labor 
Natural
1 43 28.7% 39 26% 82(27.3%)
Labor
Natural
With
Episiotomy
2 93 62% 93 62% 186(62%)
Labor
Natural 
With LP1
3 13 8.7% 18 12% 31(10.3%)
Labor
Natural
With LP2
4 1 0.6% 0 0% 1(0.3%)
Total 150 100% 150 100% 300(100%)
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y Stage in minutes
Syntometrin
e
Group
150 11.86
Oxytocin
group
150 11.74
The difference between mean duration of 3rd stage between two groups was 0.12 
minutes, which is not statistically significant (p=0.816).
MEAN BLOOD LOSS:
TABLE 8:
Frequenc
y
Mean blood loss
in  ml
Syntometrin
e
Group
150 120ml
Oxytocin
group
150 171ml
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The difference between mean blood loss between two groups was 51ml, which is 
statistically significant (p=0.000).
AMOUNT OF BLOOD LOSS IN GROUPS:
TABLE 9:
Blood loss
In groups
Syntometrin
e
group
Oxytocin
group
Total
Frequency Percentage Frequenc
y
Percentage
<100ml 2 1.3% 0 .0% 2
(0.7%)
100-150ml 146 97.3% 4 2.7% 150
(50%)
150-200ml 2 1.3% 144 96% 146
(48.7%)
>200ml 0 .0% 2 1.3% 2
(0.7%)
Total 150 100% 150 100% 300
(100%)
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97.3% of cases in syntometrine group had blood loss between 100-150ml & 96% of 
cases in oxytocin group had blood loss between 150-200ml.
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BLOOD TRANSFUSION:
TABLE 10:
Blood
Transfusion
Legend Syntometrine Group Oxytocin Group Total
Frequenc
y
Percentage Frequenc
y
Percentage
Yes 1 0 0% 3 2% 3(1%)
No 2 150 100% 147 98% 297(99%)
Total 150 100% 150 100% 300(100)%)
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2% of cases in group 2 & none of the case in group 1 had blood transfusion, which is 
not statistically significant (0.082).
SIDE EFFECTS:
None of the case in group 2 had side effects, whereas in group 1, 3.3% of cases 
developed adverse effects like nausea & vomiting.
TABLE 11:
Side 
effects
Legend Syntometrin
e
Oxytoin 
Group
Total
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Group
Frequency Percentage Frequenc
y
Percentage
Yes 1 5 3.3% 0 0% 5
1.7%)
No 2 145 96.7% 150 100% 295
98.3%
Total 150 100% 150 100% 300
100%
SIDE EFFECTS
2.001.00
C
ou
nt
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80
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40
20
0
GROUP
    1.00
    2.00
DROP IN HEMOGLOBIN OF 0.7 TO 1 GRAM PERCENT:
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TABLE 12:
↓Hemoglobi
n 
in
Grams 
percent
Legend Syntometrin
e
Group
Oxytocin 
Group
Total
Frequency Percentage Frequenc
y
Percentage
Yes 1 0 0% 3 2% 3
1%
No 2 150 100% 147 98% 297
99%
Total 150 100% 150 100% 300
100%
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Only 2% of cases in group 2 had drop in hemoglobin level of 0.7 to 1grams percent 
after delivery, which is not statistically significant (p=0.082).
BIRTH WEIGHT OF THE BABY:
       The mean birthweight of the baby in both groups was 3.1kg.
TABLE 13:
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HAEMOGLOBIN IN GRAMS PERCENTAGE
2.001.00
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DROP IN HEMOGLOBIN TO 0.7 TO 1 GRAM PERCENT
Frequenc
y
Mean weight
In kg
Syntometrin
e
Group
150 3.1
Oxytocin 
group
150 3.1
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DISCUSSION
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DISCUSSION
This  randomized  prospective  study  compares  the  efficacy  of  syntometrine 
versus oxytocin in active management of third stage of labor.
Postpartum  hemorrhage  is  an  important  cause  of  maternal  morbidity  and 
mortality, especially in developing countries where up to 28% of maternal death are 
attributed to this cause (Walder,  1997). The prophylactic use of oxytocics in the 
third stage of labor has been found to decrease the rate of postpartum bleeding by 
38%. However, there is no agreement regarding the type and route of administration 
of oxytocic drugs which offers the best efficacy and safety profile.
Several controlled trials examining the alternative oxytocic preparations used 
routinely  in  the management  of  third stage  of  labor  suggested  that  a  mixture  of 
oxytocin and ergometrine (Syntometrine) might be the drug of choice. However, the 
administration  and storage  of  syntometrine  may not  always be possible  in  some 
hospitals  or  rural  communities  due  to  discontinuous  supply  of  disposables  or 
refrigeration equipment. 
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A case  control  study28 was  carried  out  at  Jinnah  Postgraduate  Medical  in 
Department of Gynecology and Obstetrics, Karachi from January 2002 to December 
2002.  Three  hundred  patients  were  selected  by  non-probability  convenience 
sampling. The patients were grouped in three categories. Group 1 comprised of 150 
patients who received syntocinon & group 2 comprised of 150 patients who received 
syntometrine i.m after placental expulsion. The average age in group 1 was observed 
27.49±6.58  (ranging  from 17  to  43)  years  while  in  group  2,  it  was  27.17±6.27 
(ranging from 16 to 47) years. 
The  number  of  women  who  were  primigravida  in  group  1  were  44/150 
(29.3%) and 47/150 (31.1%) in group 2. Overall incidence of gravidity in this study 
was 91/300 (30.3%) primigravida & 209/300 (69.7%) multigravida. 
Blood loss was read in 3 ratings 300ml,500ml and >750ml. More than 500ml 
blood loss was observed 4.3%, with  4.7% in Group I and 4% in group 2. Thus a non 
significant difference was observed in both groups regarding the amount of blood 
loss>500ml ( p<0.05). The rate of blood loss of 300 ml  was noted in  48.7% of 
women  in  group  1  and  59.3%  of  women  in  group  2  which  was  statistically 
significant (p<0.05).
     
          In our study, there was no statistically significant difference between the two 
groups with regard to maternal age and parity. 70% of cases in syntometrine group 
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and 62.7% of cases in oxytocin group were in age group of <25years. Parity status in 
our study observed that 184/300 (61.3%) was primigravidas and 116/300 (38.7%) 
was multigravida. The number of primigravida in group 1 was 94/150 (62.7%) and 
in  group  2  was  90/150  (60%).  Use  of  syntometrine  as  part  of  AMTSL  was 
associated with statistically significant reduction in mean blood loss when compared 
with oxytocin (120 & 171ml respectively, p<0.000).
     
In a study29 carried out at Queen Alia Military Hospital (QAMH) in Amman 
between 1st February to 30th April 1997, 583 women with a singleton pregnancy and 
normal vaginal delivery were randomly allocated to receive syntometrine (n=293) or 
oxytocin (n=290). Oxytocin augmentation was used in 200 (68%) and 198 (68%) in 
syntometrine and oxytocin groups respectively. Episiotomy was performed in 250 
(85%) cases in syntometrine group and 260 (90%) cases in oxytocin group.  The 
mean birth weight of the baby in both groups was 3.2kg.
          In our study, 37 (24.7%) cases in Syntometrine group and 89 (59.3%) cases in 
oxytocin group were induced with oxytocin. 6 (4%) cases in syntometrine group and 
none of  the patient  in oxytocin group were induced with PGE2 gel  followed by 
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oxytocin.  Episiotomy was performed in 62% 0f cases in both groups.  The mean 
weight of the baby in both groups was 3.1kg.
In a prospective randomized study (2002) carried out in a university teaching 
hospital  in Hongkong, prolonged third stage>30minutes was reported in 2.8% of 
syntometrine group & 1.8% in oxytocin group.
In our study, the mean duration of third stage of labor was 11.86 minutes in 
syntometrine group and 11.74 minutes in oxytocin group.
Yuen et al (2002) reported a higher incidence of retained placenta associated 
with the use of syntometrine compared with oxytocin, but similar finding was not 
observed  in  the  current  study.  This  might  be  related  to  the  different  way  of 
delivering the placenta. In that trial, the placenta was left to deliver on its own, a 
‘hands –off approach’ whereas in our study the same was delivered by controlled 
cord  traction.  Such  interventions  allow  the  placenta  to  be  delivered  before  the 
occurrence of uterine spasm, thereby reducing the incidence of retained placenta.
McDonald et al (1993) 30conducted double blind randomized controlled trial to 
compare oxytocin alone & syntometrine for their effect  in AMTSL. Incidence of 
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PPH was similar in both groups. But the use of syntometrine was associated with 
nausea, vomiting & increased B.P.
In our study only 5 cases (3.3%) in syntometrine group developed side effects 
like nausea, vomiting.
In  a  prospective  randomized  study31 conducted  in  a  university  teaching 
hospital, Hong Kong a total of 991 women having a singleton pregnancy and vaginal 
delivery were randomized by a computer generated number to receive either 1ml 
syntometrine i.m or 10 units of syntocinon after delivery of the shoulder of fetus. 
Seven patients in syntometrine group & four patients in syntocinon group failed to 
have a paired hemoglobin test to measure the change in hemoglobin 24 hours after 
delivery.  There  is  no  difference  in  the  change  in  hemoglobin  levels  between  2 
groups. The mean level of fall in hemoglobin was 0.8grams% in syntometrine group 
and 1grams% in oxytocin group.
In our study, none of the case in syntometrine group had a fall in hemoglobin 
delivery. 2% of cases in oxytocin group had a fall in hemoglobin level of 0.7 to 
1grams% after delivery. Measurement of the change of hemoglobin concentration 
before and after  delivery is  a more objective method in assessing the amount  of 
blood loss. It is also clinically more important and relevant as it aids the decision for 
further effective management.
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SUMMARY
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SUMMARY
This  is  a  comparative  study  regarding the efficacy  of  syntometrine  versus 
oxytocin in AMTSL in reducing the mean blood loss and other adverse 3rd stage 
outcomes, carried out in ISO/KGH by blood drape which is a disposable, conical, 
graduated plastic collection bag.
In the study group of 300 patients, mean age in syntometrine group is 24.3yrs. 
The mean age in oxytocin group is  24.6yrs.  In syntometrine group,  62.7% were 
primigravida  &  37.3%  were  multigravida.  In  oxytocin  group,  60%  were 
primigravida & 40% were multigravida.
In present study, 48% of cases in syntometrine group & 51.3% of cases in 
oxytocin group were belonged to  class  4  socioeconomic  status.  52% of cases  in 
syntometrine group & 48.7% of cases in oxytocin group were belonged to class 5 
socioeconomic status. All 300 patients in our study were booked.
In the present study, 64% of cases in syntometrine group & 36% of cases in 
oxytocin group had spontaneous onset of labor. Most of the patients were delivered 
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by Labor natural with episiotomy (62%). The mean duration of 3rd stage of labor was 
11.86minutes in syntometrine group & 11.74minutes in oxytocin group.
The  mean  blood  loss  in  syntometrine  group  was  120ml  &  oxytocin  was 
171ml. 97.3% of cases in syntometrine group had blood loss between 100-150ml & 
96% of cases in oxytocin group had blood loss between 150-200ml. The mean birth 
weight of the baby was 3.1kg in both groups. 
In the present study,none of the case in oxytocin group & 3.3% of cases in 
syntometrine group developed side effects like nausea & vomiting. None of the case 
in  syntometrine  group  &  2%  of  cases  in  oxytocin  group  were  given  blood 
transfusion. 2% of cases in oxytocin group & none of the case in syntometrine group 
had a drop in  hemoglobin level.
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CONCLUSION
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 CONCLUSION
Postpartum hemorrhage is a common and serious complication of third stage 
of labor resulting in anemia and inceased morbidity in puerperium.
Routine active management is superior to expectant management in terms of 
blood loss, postpartum hemorrhage and other serious complications of third stage of 
labor.
Active management should be the routine management of choice for women 
expecting to deliver a baby by vaginal route in a health care facility.
The components of active management of 3rd stage includes giving oxytocics 
within 1 minute of birth of newborn, clamping and cutting of umbilical cord soon 
after birth, placental delivery by controlled cord traction with simultaneous counter 
traction to the uterine fundus.
The choice of drug depends on cost, facilities for storage and refrigeration, 
availability of trained personnel and assessment of trade-off between benefits and 
side effects.
77
Ergometrine  and  oxytocin  have  been  used  for  a  long  time  in  markedly 
different doses and routes of administration with varying success.
The use of syntometrine as part of routine AMTSL appears to be associated 
with  a  statistically  significant  reduction  in  mean  blood  loss  when  compared  to 
oxytocin.
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ANNEXURE
COMPARATIVE EFFICACY OF SYNTOMETRINE VERSUS OXYTOCIN 
IN ACTIVE MANAGEMENT OF THIRD STAGE OF LABOUR
Name of patient                     :
Age                                        :
OP No.                                   :
Socio Economic Status          :      I           II            III            IV         V
Education                               :
Address                            :
Obstetric Formula                  :  
Booking                                :  Booked/Unbooked
Onset of labor                         :  1. Spontaneous
                                                   2. Oxytocin induction
                                                   3. PG E2 gel induction
                                                   4. PG E2 gel induction followed by syntocinon 
Mode of delivery                     :  1. Labor natural
                                                    2. Labor natural with episiotomy
87
                                                    3. Labor natural with LP 1STdegree
                                                    4. Labor natural with LP 2nd degree
Duration of 3rd stage in minutes:
Blood loss in ml                        :    
Blood transfusion                      :  Yes/No
Side effects                                :  Yes/No
Drop in hemoglobin level          :  Yes/No
Baby weight                               :
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